Search

Novo Nordisk A-S (Class B)

Aperta

317.4 -1.24

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

316.25

Massimo

324.7

Metriche Chiave

By Trading Economics

Entrata

804M

29B

Vendite

-7.6B

78B

P/E

Media del settore

13.098

34.393

EPS

6.53

Rendimento da dividendi

3.64

Margine di Profitto

37.182

Dipendenti

77,406

EBITDA

39B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.64%

2.54%

Prossima data del Dividendo

19 ago 2025

Prossima data del' Ex Dividendo

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-639B

1.4T

Apertura precedente

318.64

Chiusura precedente

317.4

Novo Nordisk A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 ago 2025, 06:52 UTC

Utili

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 ago 2025, 06:21 UTC

Utili

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

8 ago 2025, 05:32 UTC

Discorsi di Mercato

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 ago 2025, 11:32 UTC

Utili

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 11:03 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 10:41 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 ago 2025, 20:34 UTC

Utili

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 ago 2025, 08:45 UTC

Utili

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 ago 2025, 07:19 UTC

Discorsi di Mercato
Utili

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 ago 2025, 05:50 UTC

Utili

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 ago 2025, 05:48 UTC

Utili

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 ago 2025, 05:46 UTC

Utili

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 ago 2025, 05:38 UTC

Utili

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 ago 2025, 05:37 UTC

Utili

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 ago 2025, 05:36 UTC

Utili

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 ago 2025, 05:35 UTC

Utili

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 ago 2025, 05:34 UTC

Utili

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Net Pft DKK26.5B

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Oper Pft DKK33.45B

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Sales DKK76.86B

5 ago 2025, 21:58 UTC

Utili

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 17:26 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 ago 2025, 15:15 UTC

Utili

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5 ago 2025, 10:07 UTC

Discorsi di Mercato

Novo Nordisk's Facing Challenging Times -- Market Talk

1 ago 2025, 11:10 UTC

Azioni calde

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

30 lug 2025, 11:10 UTC

Discorsi di Mercato
Utili

Novo Nordisk Suffering From Self-Inflicted Wounds -- Market Talk

30 lug 2025, 10:57 UTC

Discorsi di Mercato

Novo Nordisk's New CEO Might Need to Change U.S. Strategy -- Market Talk

30 lug 2025, 10:48 UTC

Discorsi di Mercato
Utili

Novo Nordisk's New CEO Faces Issues With No Easy Fix -- Market Talk

30 lug 2025, 10:42 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Stock Markets Beware Summer Scares. What -2-

30 lug 2025, 10:42 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo's $75 Billion Crash. -- Barrons.com

Novo Nordisk A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

9.53% in crescita

Previsioni per 12 mesi

Media 1,162.73 DKK  9.53%

Alto 1,550 DKK

Basso 720 DKK

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

2

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.